Detalhe da pesquisa
1.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med
; 385(27): 2531-2543, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965338
2.
Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Clin Infect Dis
; 61(1): 95-101, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25838288
3.
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.
Contemp Clin Trials
; 142: 107540, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38636725
4.
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.
EClinicalMedicine
; 60: 102025, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37304494
5.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
PLoS One
; 13(4): e0196239, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684092
6.
Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
Pediatr Infect Dis J
; 33(3): 301-5, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24356253